Mesothelin as a novel biomarker and immunotherapeutic target in human glioblastoma

Glioblastoma multiforme (GBM) presents the most malignant form of glioma, with a 5-year survival rate below 3% despite standard therapy. Novel immune-based therapies in improving treatment outcomes in GBM are therefore warranted. Several molecularly defined targets have been identified mediating ant...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncotarget
Autors principals: Liu, Zhenjiang, Rao, Martin, Poiret, Thomas, Nava, Silvia, Meng, Qingda, von Landenberg, Anna, Bartek, Jiri, Xie, Shanshan, Sinclair, Georges, Peredo, Inti, Dodoo, Ernest, Maeurer, Markus
Format: Artigo
Idioma:Inglês
Publicat: Impact Journals LLC 2017
Matèries:
Research Paper: Immunology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5655191/
https://ncbi.nlm.nih.gov/pubmed/29113296
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.20303
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars